Toll Free: 1-888-928-9744

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 111 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
- The report reviews Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) Overview 9 Therapeutics Development 10 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Stage of Development 10 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Therapy Area 11 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Indication 12 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Companies 16 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Universities/Institutes 21 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30 Aslan Pharmaceuticals Pte. Ltd. 30 Boehringer Ingelheim GmbH 31 GamaMabs Pharma S.A. 32 Hanmi Pharmaceuticals, Co. Ltd. 33 HEC Pharm Co., Ltd. 34 Jiangsu Kanion Pharmaceutical Co., Ltd. 35 Minerva Neurosciences, Inc. 36 Pfizer Inc. 37 Puma Biotechnology, Inc. 38 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 39 Sihuan Pharmaceutical Holdings Group Ltd. 40 Zensun (Shanghai) Sci & Tech Co., Ltd. 41 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Drug Profiles 42 afatinib dimaleate - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 dacomitinib - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 FCN-411 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 MIN-301 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Monoclonal Antibodies to Antagonize HER4 for Oncology - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 neratinib - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Neucardin - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 NRG-4 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 NT-113 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 PB-357 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 pirotinib - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 poziotinib - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 sirotinib - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 SKLB-1206 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 varlitinib - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 yinlitinib - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Z-650 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Dormant Projects 93 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Discontinued Products 95 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Featured News & Press Releases 96 Jun 05, 2016: Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting 96 May 18, 2016: Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting 97 May 09, 2016: The Lancet Oncology publishes head-to-head study comparing first and second generation targeted therapies in treatment of EGFR-mutation positive non-small cell lung cancer 97 Apr 21, 2016: New Data On Aslan's Varlitinib To Be Published At 2016 Annual Meeting Of American Society Of Cancer Oncology 99 Apr 20, 2016: Puma Biotechnology's Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016 99 Apr 15, 2016: FDA approves Gilotrif (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung 100 Apr 14, 2016: Puma Biotechnology's NEfERT-T Phase II Study Published Online in JAMA Oncology 101 Apr 13, 2016: Head-to-head study demonstrating Gilotrif (afatinib) significantly improved clinical outcomes compared to Iressa (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology 102 Apr 07, 2016: Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung 104 Apr 04, 2016: Precision medicine brings new hope to those with advanced urothelial cancer 105 Mar 28, 2016: Puma Biotechnology Updates Timeline for Filing New Drug Application For Neratinib 106 Mar 18, 2016: Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016 107 Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor 108 Feb 29, 2016: European Committee for Medicinal Products for Human Use recommends approval of Giotrif (afatinib) for advanced squamous cell cancer of the lung 108 Feb 23, 2016: Aslan Pharmaceuticals To Present New Data On Varlitinib At Annual American Association For Cancer Research Meeting 109 Appendix 110 Methodology 110 Coverage 110 Secondary Research 110 Primary Research 110 Expert Panel Validation 110 Contact Us 110 Disclaimer 111
List of Tables
Number of Products under Development for, H1 2016 10 Number of Products under Development by Therapy Area, H1 2016 11 Number of Products under Development by Indication, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 (Contd..1) 18 Products under Development by Companies, H1 2016 (Contd..2) 19 Products under Development by Companies, H1 2016 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H1 2016 21 Products under Investigation by Universities/Institutes, H1 2016 22 Assessment by Monotherapy/Combination Products, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016 30 Pipeline by Boehringer Ingelheim GmbH, H1 2016 31 Pipeline by GamaMabs Pharma S.A., H1 2016 32 Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 33 Pipeline by HEC Pharm Co., Ltd., H1 2016 34 Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016 35 Pipeline by Minerva Neurosciences, Inc., H1 2016 36 Pipeline by Pfizer Inc., H1 2016 37 Pipeline by Puma Biotechnology, Inc., H1 2016 38 Pipeline by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., H1 2016 39 Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 40 Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 41 Dormant Projects, H1 2016 93 Dormant Projects (Contd..1), H1 2016 94 Discontinued Products, H1 2016 95


List of Figures
Number of Products under Development for, H1 2016 10 Number of Products under Development by Therapy Area, H1 2016 11 Number of Products under Development by Top 10 Indication, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 23 Number of Products by Mechanism of Actions, H1 2016 24 Number of Products by Stage and Mechanism of Actions, H1 2016 24 Number of Products by Routes of Administration, H1 2016 26 Number of Products by Stage and Routes of Administration, H1 2016 26 Number of Products by Molecule Types, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 28

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify